Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited | Synapse
September 5, 2025Open Access
Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Puntos clave
CAR T-cells effectively reduced myeloma growth, even under limited BCMA expression.
The key metric was cytokine production, specifically IFNγ and IL-2, measured at 24 hours.
Observational analysis showed cytokine levels in CAR T-cells after co-culturing with K562 tumor cells.
Findings suggest potential for CAR T-cells in cases with variable BCMA expression, requiring further validation.
Resumen
Cytokine production (IFNγ and IL-2) of CAR T-cells in co-culture with K562 cell lines with different expression of CD229 antigen tumor cells at the 24-hr time point measured by ELISA.